TY - JOUR
T1 - Prostate-specific Membrane Antigen Reporting and Data System Version 2.0
AU - Werner, Rudolf A.
AU - Hartrampf, Philipp E.
AU - Fendler, Wolfgang P.
AU - Serfling, Sebastian E.
AU - Derlin, Thorsten
AU - Higuchi, Takahiro
AU - Pienta, Kenneth J.
AU - Gafita, Andrei
AU - Hope, Thomas A.
AU - Pomper, Martin G.
AU - Eiber, Matthias
AU - Gorin, Michael A.
AU - Rowe, Steven P.
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/11
Y1 - 2023/11
N2 - Prostate-specific Membrane Antigen Reporting and Data System (PSMA-RADS) was introduced for standardized reporting, and PSMA-RADS version 1.0 allows classification of lesions based on their likelihood of representing a site of prostate cancer on PSMA-targeted positron emission tomography (PET). In recent years, this system has extensively been investigated. Increasing evidence has accumulated that the different categories reflect their actual meanings, such as true positivity in PSMA-RADS 4 and 5 lesions. Interobserver agreement studies demonstrated high concordance among a broad spectrum of 68Ga- or 18F-labeled, PSMA-directed radiotracers, even for less experienced readers. Moreover, this system has also been applied to challenging clinical scenarios and to assist in clinical decision-making, for example, to avoid overtreatment in oligometastatic disease. Nonetheless, with an increasing use of PSMA-RADS 1.0, this framework has shown not only benefits, but also limitations, for example, for follow-up assessment of locally treated lesions. Thus, we aimed to update the PSMA-RADS framework to include a refined set of categories in order to optimize lesion-level characterization and best assist in clinical decision-making (PSMA-RADS version 2.0).
AB - Prostate-specific Membrane Antigen Reporting and Data System (PSMA-RADS) was introduced for standardized reporting, and PSMA-RADS version 1.0 allows classification of lesions based on their likelihood of representing a site of prostate cancer on PSMA-targeted positron emission tomography (PET). In recent years, this system has extensively been investigated. Increasing evidence has accumulated that the different categories reflect their actual meanings, such as true positivity in PSMA-RADS 4 and 5 lesions. Interobserver agreement studies demonstrated high concordance among a broad spectrum of 68Ga- or 18F-labeled, PSMA-directed radiotracers, even for less experienced readers. Moreover, this system has also been applied to challenging clinical scenarios and to assist in clinical decision-making, for example, to avoid overtreatment in oligometastatic disease. Nonetheless, with an increasing use of PSMA-RADS 1.0, this framework has shown not only benefits, but also limitations, for example, for follow-up assessment of locally treated lesions. Thus, we aimed to update the PSMA-RADS framework to include a refined set of categories in order to optimize lesion-level characterization and best assist in clinical decision-making (PSMA-RADS version 2.0).
KW - Prostate carcinoma
KW - Prostate-specific membrane antigen
KW - Reporting and data system
KW - Structured reporting
UR - http://www.scopus.com/inward/record.url?scp=85165267074&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2023.06.008
DO - 10.1016/j.eururo.2023.06.008
M3 - Article
C2 - 37414701
AN - SCOPUS:85165267074
SN - 0302-2838
VL - 84
SP - 491
EP - 502
JO - European Urology
JF - European Urology
IS - 5
ER -
